By Fineline Cube 
CARsgen Therapeutics (HKG: 2171) reported interim results for the first half of 2026, highlighted by a landmark regulatory milestone: Satricabtagene Autoleucel received NMPA approval for market launch in June 2026, becoming the world’s first and only CAR‑T product approved for the treatment of solid tumors. The company recorded revenue of approximately RMB 62 million, primarily from Zevorcabtagene Autoleucel, and expects sufficient cash to fund operations into 2030.
1H 2026 Financial & Operating Highlights
| Item | 1H 2026 |
|---|---|
| Revenue | ~RMB 62 million (primarily Zevorcabtagene Autoleucel) |
| Zevorcabtagene Autoleucel Orders | 110 valid orders from commercial partner Huadong Medicine |
| Cash & Cash Equivalents (30 Jun 2026) | ~RMB 1.4 billion |
| Expected Cash (end‑2026) | No less than RMB 1.2 billion |
| Cash Runway | Sufficient to fund operations into 2030 |
Commercial & Clinical Milestones
- Zevorcabtagene Autoleucel: 110 valid orders received from commercial partner Huadong Medicine during the first half, driving the company’s revenue generation.
- Satricabtagene Autoleucel: NMPA approval in June 2026 makes it the world’s first and only CAR‑T therapy approved for solid tumors — a global first for the cell‑therapy field.
- ASCO 2026 Data: Long‑term follow‑up results from the first‑line sequential therapy of Satricabtagene Autoleucel for gastric cancer were presented at the 2026 ASCO Annual Meeting, reinforcing the product’s clinical profile in earlier treatment settings.
Liquidity & Cash Runway
- Cash and cash equivalents stood at approximately RMB 1.4 billion as of 30 June 2026.
- Management expects cash and cash equivalents to remain no less than RMB 1.2 billion by end‑2026.
- Taking into account operational factors, CARsgen expects sufficient cash to fund operations into 2030, providing substantial runway for commercialization and pipeline development.
Market Impact & Outlook
- Category‑Defining Approval: Satricabtagene Autoleucel’s status as the first approved CAR‑T for solid tumors breaks a long‑standing barrier in cell therapy, opening a commercial beachhead in a field previously confined to hematologic malignancies.
- Commercial Traction: 110 first‑half orders for Zevorcabtagene Autoleucel through Huadong Medicine signal building market adoption of CARsgen’s marketed portfolio.
- Front‑Line Expansion Potential: Long‑term ASCO follow‑up data in first‑line gastric cancer supports future label and setting expansion for Satricabtagene Autoleucel.
- Balance‑Sheet Resilience: A stated cash runway into 2030 reduces financing risk during the critical early commercialization years.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding CARsgen’s cash position, commercial adoption, and product development. Actual results may differ due to risks including market uptake, pricing and reimbursement dynamics, clinical outcomes, and competitive developments.-Fineline Info & Tech